Option Care Health (NASDAQ:OPCH) Downgraded by Wall Street Zen to Hold

Option Care Health (NASDAQ:OPCH) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

OPCH has been the topic of several other reports. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Option Care Health from $31.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. National Bank Financial set a $37.00 price target on shares of Option Care Health in a research note on Tuesday, January 27th. Barrington Research lifted their price objective on shares of Option Care Health from $38.00 to $42.00 and gave the company an “outperform” rating in a research note on Friday, January 16th. Weiss Ratings restated a “hold (c)” rating on shares of Option Care Health in a research report on Monday, December 29th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Option Care Health in a report on Tuesday, January 13th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Option Care Health has a consensus rating of “Moderate Buy” and an average target price of $37.58.

Option Care Health Trading Up 1.8%

NASDAQ:OPCH opened at $32.46 on Friday. Option Care Health has a 12 month low of $24.24 and a 12 month high of $36.80. The company has a current ratio of 1.53, a quick ratio of 1.05 and a debt-to-equity ratio of 0.87. The firm’s 50 day moving average is $33.99 and its 200 day moving average is $30.57. The stock has a market capitalization of $5.08 billion, a PE ratio of 25.36, a price-to-earnings-growth ratio of 1.84 and a beta of 0.84.

Option Care Health (NASDAQ:OPCH) last released its earnings results on Tuesday, February 24th. The company reported $0.46 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.46. Option Care Health had a return on equity of 18.57% and a net margin of 3.67%.The business had revenue of $1.47 billion during the quarter, compared to the consensus estimate of $1.46 billion. During the same period last year, the business posted $0.44 earnings per share. The business’s revenue for the quarter was up 8.8% on a year-over-year basis. Sell-side analysts expect that Option Care Health will post 1.22 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in OPCH. V Square Quantitative Management LLC bought a new stake in Option Care Health during the fourth quarter valued at $25,000. Cornerstone Planning Group LLC raised its holdings in shares of Option Care Health by 7,621.4% in the 3rd quarter. Cornerstone Planning Group LLC now owns 1,081 shares of the company’s stock valued at $30,000 after acquiring an additional 1,067 shares in the last quarter. Advisory Services Network LLC bought a new stake in shares of Option Care Health during the 3rd quarter valued at about $35,000. McIlrath & Eck LLC purchased a new position in shares of Option Care Health during the second quarter worth about $37,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in shares of Option Care Health in the third quarter worth approximately $38,000. Institutional investors own 98.05% of the company’s stock.

About Option Care Health

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.